Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in adolescents with moderately to severely active ulcerative colitis
2022-500345-25-00Phase 2Authorised
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of etrasimod in autoimmune colitis, sponsored by Arena Pharmaceuticals, Inc. Primary endpoint: Clinical remission by modified Mayo score at Week 52. Planned start Jan 2023; status: authorised.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-500345-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500345-25-00.